Articles Posted in Uncategorized

Published on:

pills2New data suggests an association between melanoma skin cancer and Viagra. This has led many patients suffering from erectile dysfunction to question whether the benefits of this drug justify the risk of death that many accompany it.

If you or someone you love has developed melanoma while taking Viagra, you may have an injury or wrongful death lawsuit against Pfizer who has never adequately warned patients and their doctors of this risk. If you believe you have a claim, call our lawyers for free at 800-553-8082 or get a free Internet consultation. We can discuss your options with you.

The Association Between Viagra and Melanoma

The understanding of the potential risks of melanoma with Viagra took flight in 2014 for the general public when Harvard Medical School released a new study indicating that Viagra users were 84% more likely to develop melanoma skin cancer.

Continue Reading

Published on:

testosterone2
Testosterone supplements have found themselves in the news quite a bit lately.  Unfortunately, for manufacturers, this is not good news. Because these lawsuit are on the fast track to being a very big deal.

There is a lot of research coming out with sudden fury that suggests that testosterone treatments for men can cause an increased risk of heart attacks and strokes that can lead to serious injury and death.  A study published this week in the medical journal Plos One, indicated that researchers found a two-fold increase in the risk of heart attack in the three months after an initial prescription among men aged 65 years and older, and a two to three-fold increase among younger men with a history of heart disease.  This is huge, especially considering millions of men are taking these hormonal treatments, and many are learning for the first time of the extent of the risk.

Products in this category are:

Published on:

August brought changes to thirty-four (34) medical product labels, with changes to the prescribing information to include any of the following areas: boxed warnings, contraindications, warnings, precautions, adverse reactions, patient package insert, and medication guide.

pillsFor a complete detailed accounting of the label changes, refer to the summary of meds. By clicking onto the drug name, you will be able to view the detailed summary, which will identify the safety labeling section and revised subsection, as well as a brief summary of the new or modified safety information.

The following medications have been affected:

Published on:

It took a New Jersey federal jury one hour and twenty minutes to determine that Fosamax did not cause a Plaintiff’s femur fracture.  In the first verdict in a Fosamax case where the Plaintiff claims that the osteoporosis drug weakened her thigh bone, the jury said that Plaintiff did not prove her case.

After having taken Fosamax for eight years, Plaintiff, now fifty-eight, fractured her right femur requiring surgical repair.  She sued alleging that Fosamax caused her atypical femur fracture, and that the manufacture, Merck, failed to warn her doctor about the risk.  Merck, pleased with the verdict, stated that the company provided appropriate and timely information about Fosamax to consumers.

Plaintiff’s suit had been transferred into the Fosamax femur fracture MDL, sometimes referred to as “Fosamax II” as an earlier Fosamax MDL was formed to deal with claims of osteonecrosis of the jaw (ONJ).  Merck has said that there are about 3,300 Fosamax femur fracture cases, and about 1,230 ONJ cases.

Published on:

McNeil-PPC Inc. and Johnson & Johnson have asked that all New Jersey state court Tylenol liver injury cases be centralized before one Judge in the Middlesex County Superior Court, in order to avoid duplicative discovery, inconsistent rulings, and to conserve resources of the judiciary and the parties.  There are currently fourteen Tylenol cases pending in New Jersey state courts with Plaintiffs from twelve different states.

In their request that stated that since the federal Tylenol injury cases were centralized in April, thirty-three new federal cases have been transferred into the multidistrict litigation (MDL).

The defendants are refuting the plaintiffs’ claims that McNeil and Johnson & Johnson failed to warn about the risk of liver injury.  They claim that the risk has been known “for decades” and further claim that the FDA has repeatedly said that Tylenol and acetaminophen are safe when used as directed, and when recommended dosages are not exceeded.

Published on:

medicationJune brought changes to forty-four (44) medical product labels (up slightly from 40 changes in May), with changes to the prescribing information to include any of the following areas: boxed warnings, contraindications, warnings, precautions, adverse reactions, patient package insert, and medication guide.

For a complete detailed accounting of the label changes, refer to the summary of meds. By clicking onto the drug name, you will be able to view the detailed summary, which will identify the safety labeling section and revised subsection, as well as a brief summary of the new or modified safety information.

The following medications have been affected:

Published on:

pills2The Food and Drug Administration (FDA) has been considering making changes to its labeling rules with regard to generic drugs.  The changes could provide generic drug users with more protection.

Currently, those that have been injured by a brand-name drug can win compensation from the manufacturer if it can be shown that the drug was unreasonably dangerous or that the warning label did not disclose the risks properly.  Those injured by a generic medicine?  Not so much.  Those injured by a generic medicine can’t hold the manufacturer liable as long as the drug maker used the same active ingredients and displayed the same warnings as the brand-name drug.  Crazy, huh?

All of that could be changed by a new rule that the FDA expects to formally propose in September.  The new rule would “revise and clarify procedures for changes to the labeling” of approved drugs.  This will include both brand names and generics.  This change would either enable or require (not yet clear based on the information provided by the FDA) drug makers to announce possible changes to their warnings while the FDA is considering the warning.

Published on:

medicationThe FDA has shut down 1,677 sites for selling counterfeit or substandard medication, or for selling drugs without appropriate safeguards.  Other sites received regulatory warnings.

While the prices look good, you never really know what you’re getting.  These products can have too much or too little of the active ingredient that people need for the treatment of their disease, and some could have toxic ingredients.  Several of the sites had sleek interfaces and names that could easily be confused with legitimate pharmacies.  Walgreens-Store.com for example – the drugstore chain is actually Walgreens.com.

Though many of the sites present themselves as Canadian, most of them are based overseas – China, India, Pakistan, all around the world.  The National Association of Boards of Pharmacy recently performed an analysis of more than 10,000 websites and found that 97% did not fully comply with state and federal regulations. 88% didn’t require a valid prescription, and almost half of them sold medicines lacking FDA approval.

Published on:

painA Georgia federal jury ruled for the Defendant this week, determining that Mentor Worldwide LLC was not negligent in its design, manufacture, and sale of the ObTape pelvic mesh.

Also known as a vaginal sling, Plaintiff was implanted with the ObTape in December 2004 to treat bladder prolapse and urinary incontinence.  Six months later, she was diagnosed with vaginitis and a doctor found that the mesh had extruded into her vagina.

She filed suit claiming that the ObTape caused vaginal erosion and required surgical removal.  She further claimed that the pore size of the ObTape was insufficient to allow for tissue to become integrated into the device.  She said the mesh created a propensity for infection and/or abscess, resulting in an unreasonably high rate of infection, abscesses, tissue erosion and mesh extrusion.

Published on:

May brought changes to forty (40) medical product labels (down from 48 changes in April), with changes to the prescribing information to include any of the following areas: boxed warnings, contraindications, warnings, precautions, adverse reactions, patient package insert, and medication guide.

For a complete detailed accounting of the label changes, refer to the summary of meds. By clicking onto the drug name, you will be able to view the detailed summary, which will identify the safety labeling section and revised subsection, as well as a brief summary of the new or modified safety information.

The following medications have been affected: